arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

RenovoRx, Inc.

RNXT
$1.70 ▲ +0.02 (+1.49%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
7 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

RenovoRx, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $60.1M
Dividend Yield
Revenue Growth 2511.6%
Op. Margin
ROIC -230.8%
FCF / Share $-0.31
Trailing P/E
Price / Book 11.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

7-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.12M
↑ +2511.6%
Net Income Profit after all expenses
$-11.17M
↓ -26.7%
FCF / Share Free cash flow per share
$-0.31
↑ +24.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
2
Financial Health
5
Cash Quality
65

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters